Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29940742 | 1.00 | CYP1A2 (0.45) | CYP1A2TRPM4CYP2A6NQO2NCF1 | |
| SCHEMBL637928 | 0.77 | CYP2A6 (0.50) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| SCHEMBL162040 | 0.77 | TRPM4 (0.48) | CYP1A2TRPM4CYP2A6NQO2MAPT | |
| SCHEMBL9629001 | 0.77 | TRPM4 (0.48) | CYP1A2TRPM4CYP2A6NQO2MAPT | |
| SCHEMBL266459 | 0.77 | CYP1A2 (0.64) | CYP1A2NCF1MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL13829913 | 0.77 | CYP1A2 (0.42) | CYP1A2CYP2A6MAPTL3MBTL1ALDH1A1 | |
| SCHEMBL30199873 | 0.77 | CYP1A2 (0.64) | CYP1A2NCF1MAPTL3MBTL1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL13730044 | 0.76 | CYP2A6 (0.48) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL28363251 | 0.76 | MAPT (0.50) | CYP1A2CYP2A6NCF1MAPTL3MBTL1 | |
| SCHEMBL3083764 | 0.74 | TRPM4 (0.45) | CYP1A2TRPM4CYP2A6NQO2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | claimed |
| EP-3781711-B1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-11-20 | — | — | EP | claimed |
| US-11505827-B2 | Systems and methods for determining genetic data | Roche Sequencing Solutions, Inc. (US) | 2022-11-22 | — | — | US | claimed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | claimed |
| EP-3781711-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-24 | — | — | EP | claimed |
| WO-2019204585-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-24 | — | — | WO | claimed |
| US-20190292591-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2019-09-26 | — | — | US | claimed |
| US-10260093-B2 | Systems and methods for determining genetic data | Genia Technologies, Inc. (US) | 2019-04-16 | — | — | US | claimed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | claimed |
| US-20140303032-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Roche Sequencing Solutions, Inc. | 2014-10-09 | — | — | US | claimed |
| WO-2013067208-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2013-05-10 | — | — | WO | claimed |
| EP-1373561-B1 | USE OF MASS-MATCHED NUCLEOTIDES IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | UNIV BOSTON (US) | 2009-02-18 | — | — | EP | claimed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | claimed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | claimed |
| JP-2004514440-A | — | — | 2004-05-20 | — | — | JP | claimed |
| US-20040077004-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and highly multiplexed nucleic acid sequencing | TRUSTEES OF BOSTON UNIVERSITY, THE | 2004-04-22 | — | — | US | claimed |
| US-6660229-B2 | Synthesizing extension products of the target nucleic acid in the presence of chain terminating nucleotides and mass-matched nucleotides; determining the mass of each extension product; and calculating a mass shift | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-12-09 | — | — | US | claimed |
| EP-1348035-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | Riken (JP) | 2003-10-01 | — | — | EP | claimed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | claimed |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | ILLUMINA, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ILLUMINA INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4574993-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12338486-B2 | Single-stranded break detection in double-stranded DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250157582-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-3540076-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-3733875-B1 | METHOD FOR ASSEMBLING A PROTEIN | ROCHE SEQUENCING SOLUTIONS INC (US) | 2025-01-01 | — | — | EP | disclosed |
| EP-3781711-B1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INST TECHNOLOGY (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2024064962-A2 | IMMUNO-PCR AND NEXT GENERATION SEQUENCING FOR PRECISE ANTIGEN QUANTITATION | SLINGSHOT BIOSCIENCES, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| WO-2024006783-A2 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ILLUMINA, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| EP-4276194-A2 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| EP-3978621-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2023-07-27 | — | — | US | disclosed |
| US-11674174-B2 | Nucleic acid sequences using tags | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230056324-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11505827-B2 | Systems and methods for determining genetic data | Roche Sequencing Solutions, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| US-11499190-B2 | Nucleic acid sequencing using tags | Roche Sequencing Solutions, Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20220205037-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SEQUENOM, INC. | 2022-06-30 | — | — | US | disclosed |
| US-20220154265-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLIED BIOSYSTEMS, LLC | 2022-05-19 | — | — | US | disclosed |
| US-11306354-B2 | Methods and compositions for analyzing nucleic acid | SEQUENOM, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3978621-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3943607-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | The Scripps Research Institute (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11225686-B2 | Compositions, methods, and kits for amplifying nucleic acids | APPLIED BIOSYSTEMS, LLC (US) | 2022-01-18 | — | — | US | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| EP-3663409-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2021-10-06 | — | — | EP | disclosed |
| CN-113164589-A | Compositions and methods for modulating monocyte and macrophage inflammatory phenotype and immunotherapy uses thereof | 维西欧制药公司 | 2021-07-23 | — | — | CN | disclosed |
| EP-3129493-B1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | SCRIPPS RESEARCH INST (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2021110720-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-06-10 | — | — | WO | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-20210071240-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-03-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| EP-3781711-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20200407786-A1 | NUCLEIC ACID SEQUENCING USING TAGS | ROCHE SEQUENCING SOLUTIONS INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-20200377944-A1 | COMPOSITIONS AND METHODS FOR UNIDIRECTIONAL NUCLEIC ACID SEQUENCING | ROCHE SEQUENCING SOLUTIONS INC (US) | 2020-12-03 | — | — | US | disclosed |
| EP-3733874-A1 | UNIDIRECTIONAL SEQUENCING USING PANDOMERS | Genia Technologies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3733875-A1 | METHOD FOR ASSEMBLING A PROTEIN | Genia Technologies, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-10822650-B2 | Nucleic acid sequencing using tags | Roche Sequencing Solutions, Inc. (US) | 2020-11-03 | — | — | US | disclosed |
| EP-3728635-A1 | COMPOSITIONS AND METHODS FOR UNIDIRECTIONAL NUCLEIC ACID SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2020-10-28 | — | — | EP | disclosed |
| EP-3354643-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200294625-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2020-09-17 | — | — | US | disclosed |
| US-20200248250-A1 | NUCLEIC ACID SEQUENCES USING TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-08-06 | — | — | US | disclosed |
| EP-3663409-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20200140937-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLIED BIOSYSTEMS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-10622094-B2 | Methods and processes for non-invasive assessment of genetic variations | SEQUENOM, INC. (US) | 2020-04-14 | — | — | US | disclosed |
| EP-2917372-B1 | NUCLEIC ACID SEQUENCING USING TAGS | GENIA TECH INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10604796-B2 | Compositions, methods, and kits for amplifying nucleic acids | APPLIED BIOSYSTEMS, LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-20200095591-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE | 2020-03-26 | — | — | US | disclosed |
| EP-2852680-B1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2019-12-25 | — | — | EP | disclosed |
| US-10513706-B2 | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-12-24 | — | — | US | disclosed |
| WO-2019204585-A1 | SINGLE-STRANDED BREAK DETECTION IN DOUBLE-STRANDED DNA | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-10-24 | — | — | WO | disclosed |
| US-20190292591-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2019-09-26 | — | — | US | disclosed |
| EP-3540076-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | SPRING BREAK PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3524252-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-10376533-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-1994182-B1 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-10260093-B2 | Systems and methods for determining genetic data | Genia Technologies, Inc. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| US-20190040468-A1 | Microarray for detection of mutations in beta-globin genes and detection method thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3432881-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2019-01-30 | — | — | EP | disclosed |
| EP-3011051-B1 | METHOD FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM INC (US) | 2019-01-30 | — | — | EP | disclosed |
| CN-109069484-A | Purposes of the DDX3 inhibitor as antiproliferative | 锡耶纳大学医院 | 2018-12-21 | — | — | CN | disclosed |
| EP-3354643-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | Aerie Pharmaceuticals, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2097527-B1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS (DK) | 2018-08-01 | — | — | EP | disclosed |
| US-9920361-B2 | Methods and compositions for analyzing nucleic acid | SEQUENOM, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3053913-B1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | AERIE PHARMACEUTICALS INC (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20180030524-A1 | NUCLEIC ACID SEQUENCING USING TAGS | ROCHE SEQUENCING SOLUTIONS INC (US) | 2018-02-01 | — | — | US | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2018-01-18 | — | — | US | disclosed |
| EP-2915815-B1 | NEW MODIFIED NUCLEIC ACID | TAKEDA PHARMACEUTICALS CO (JP) | 2018-01-17 | — | — | EP | disclosed |
| EP-3256461-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2017-12-20 | — | — | EP | disclosed |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2017-10-26 | — | — | US | disclosed |
| WO-2017162834-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017162834-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2017-09-28 | — | — | WO | disclosed |
| US-20170241948-A1 | NUCLEIC ACID SEQUENCES USING TAGS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-08-24 | — | — | US | disclosed |
| US-9725474-B2 | Modified nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-08 | — | — | US | disclosed |
| US-20170218360-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | MIRRX THERAPEUTICS A/S (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9677123-B2 | Degenerate nucleobase analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9605309-B2 | Nucleic acid sequencing using tags | Genia Technologies, Inc. (US) | 2017-03-28 | — | — | US | disclosed |
| EP-3138928-A1 | SELECTION OF PROBE PAIRS FOR MICROARRAY DETECTION OF MUTATIONS | Mitsubishi Rayon Co. Ltd. (JP) | 2017-03-08 | — | — | EP | disclosed |
| EP-3129493-A2 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | The Scripps Research Institute (US) | 2017-02-15 | — | — | EP | disclosed |
| US-20170029829-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-02-02 | — | — | US | disclosed |
| US-9539276-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9453218-B2 | Method for producing a nucleic acid library having at least two adjacent variable codon triplets | FUHRMANN MARKUS (DE) | 2016-09-27 | — | — | US | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
| WO-2016128541-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2016-08-18 | — | — | WO | disclosed |
| EP-3011051-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2748319-B1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160024566-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLERA CORPORATION | 2016-01-28 | — | — | US | disclosed |
| US-20160016983-A1 | New Modified Nucleic Acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. | 2015-12-31 | — | — | US | disclosed |
| EP-2956145-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2015-12-23 | — | — | EP | disclosed |
| US-20150329864-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-11-19 | — | — | US | disclosed |
| WO-2015157555-A2 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-10-15 | — | — | WO | disclosed |
| US-9138442-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2917372-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2915815-A1 | NEW MODIFIED NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-09 | — | — | EP | disclosed |
| US-20150184241-A1 | MICROARRAY FOR DETECTION OF MUTATIONS IN beta-GLOBIN GENES AND DETECTION METHOD THEREOF | MITSUBISHI RAYON CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-9040234-B2 | Oligonucleotide analogs as therapeutic agents | SPRING BANK PHARMACEUTICALS, INC. (US) | 2015-05-26 | — | — | US | disclosed |
| EP-2852680-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | Sequenom, Inc. (US) | 2015-04-01 | — | — | EP | disclosed |
| EP-2832863-A1 | MICROARRAY FOR DETECTION OF MUTATIONS IN -GLOBIN GENES AND DETECTION METHOD THEREOF | Mitsubishi Rayon Co., Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
| US-20150005176-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. | 2015-01-01 | — | — | US | disclosed |
| WO-2014205401-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. (US) | 2014-12-24 | — | — | WO | disclosed |
| US-20140357531-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140303032-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Roche Sequencing Solutions, Inc. | 2014-10-09 | — | — | US | disclosed |
| WO-2014127378-A2 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |
| EP-2748319-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | Fuhrmann, Markus (DE) | 2014-07-02 | — | — | EP | disclosed |
| WO-2014074727-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2014-05-15 | — | — | WO | disclosed |
| US-20140134616-A1 | NUCLEIC ACID SEQUENCING USING TAGS | Genia Technologies, Inc. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140004515-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLERA CORPORATION | 2014-01-02 | — | — | US | disclosed |
| WO-2013177086-A1 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | SEQUENOM, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130310260-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID | SEQUENOM, INC (US) | 2013-11-21 | — | — | US | disclosed |
| WO-2013124211-A1 | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY HAVING AT LEAST TWO ADJACENT VARIABLE CODON TRIPLETS | FUHRMANN MARKUS (DE) | 2013-08-29 | — | — | WO | disclosed |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| EP-2458011-B1 | Compositions, methods, and kits for amplifying nucleic acids | LIFE TECHNOLOGIES CORP (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2611451-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | Spring Bank Pharmaceuticals, Inc. (US) | 2013-07-10 | — | — | EP | disclosed |
| US-8470531-B2 | Compositions, methods, and kits for amplifying nucleic acids | APPLIED BIOSYSTEMS, LLC (US) | 2013-06-25 | — | — | US | disclosed |
| WO-2013067208-A1 | SYSTEMS AND METHODS FOR DETERMINING GENETIC DATA | Genia Technologies, Inc. (US) | 2013-05-10 | — | — | WO | disclosed |
| EP-1544294-B1 | NUCLEOSIDES OR NUCLEOTIDES HAVING NOVEL UNNATURAL BASES AND USE THEREOF | RIKEN (JP) | 2013-04-10 | — | — | EP | disclosed |
| US-8404651-B2 | Compositions and methods for treating viral infections | SPRING BANK PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-1943348-B1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | LIFE TECHNOLOGIES CORP (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2458011-A1 | Compositions, methods, and kits for amplifying nucleic acids | Life Technologies Corporation (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2012030626-A2 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110262898-A1 | Compositions, Methods, and Kits for Amplifying Nucleic Acids | APPLIED BIOSYSTEMS, LLC (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110097716-A1 | Methods for Detecting Oligonucleotides | NOVARTIS AG (CH) | 2011-04-28 | — | — | US | disclosed |
| EP-1219607-B1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO (JP) | 2011-04-06 | — | — | EP | disclosed |
| EP-2271351-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100184159-A1 | Compositions, Methods, and Kits for Selective Amplification of Nucleic Acids | APPLIED BIOSYSTEMS, LLC (US) | 2010-07-22 | — | — | US | disclosed |
| US-7745417-B2 | Nucleosides or nucleotides having novel unnatural bases and use thereof | RIKEN (JP) | 2010-06-29 | — | — | US | disclosed |
| EP-2183390-A1 | METHODS FOR DETECTING OLIGONUCLEOTIDES | Novartis Ag (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20100055798-A1 | Degenerate Nucleobase Analogs | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| CN-101641440-A | Oligonucleotides for modulating target RNA activity | QUERDENKER APS DK | 2010-02-03 | — | — | CN | disclosed |
| US-20100021914-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS | 2010-01-28 | — | — | US | disclosed |
| WO-2009146123-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SPRING BANK (US) | 2009-12-03 | — | — | WO | disclosed |
| EP-1856280-A4 | COMPOSITIONS, METHODS, AND KITS FOR SELECTIVE AMPLIFICATION OF NUCLEIC ACIDS | APPLERA CORP (US) | 2009-09-09 | — | — | EP | disclosed |
| EP-2097527-A2 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | Querdenker Aps (DK) | 2009-09-09 | — | — | EP | disclosed |
| US-7576198-B1 | Integrase inhibitors containing aromatic heterocycle derivatives | SHIONOGI & CO., LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| WO-2009024599-A1 | METHODS FOR DETECTING OLIGONUCLEOTIDES | NOVARTIS AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| EP-1373561-B1 | USE OF MASS-MATCHED NUCLEOTIDES IN THE ANALYSIS OF OLIGONUCLEOTIDE MIXTURES AND IN HIGHLY MULTIPLEXED NUCLEIC ACID SEQUENCING | UNIV BOSTON (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080305966-A1 | Capture Probe Design for Efficient Hybridisation | UNIVERSITE LAVAL (CA) | 2008-12-11 | — | — | US | disclosed |
| EP-1994182-A2 | DEGENERATE NUCLEOBASE ANALOGS | Siemens Healthcare Diagnostics Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| EP-1943348-A2 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | Applera Corporation (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2008061537-A2 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | QUERDENKER APS (DK) | 2008-05-29 | — | — | WO | disclosed |
| US-7374882-B2 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2008-05-20 | — | — | US | disclosed |
| EP-1778864-A4 | CAPTURE PROBE DESIGN FOR EFFICIENT HYBRIDISATION | INFECTIO RECHERCHE INC (CA) | 2008-03-19 | — | — | EP | disclosed |
| EP-1856280-A2 | COMPOSITIONS, METHODS, AND KITS FOR SELECTIVE AMPLIFICATION OF NUCLEIC ACIDS | Applera Corporation (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20070259827-A1 | Compositions and methods for enhancing discriminatory RNA interference | UNIVERSITY OF MASSACHUSETTS (US) | 2007-11-08 | — | — | US | disclosed |
| WO-2007106690-A2 | DEGENERATE NUCLEOBASE ANALOGS | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070212695-A1 | Compositions, methods, and kits for selective amplification of nucleic acids | APPLERA CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070212704-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLERA CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| WO-2007087451-A2 | COMPOSITIONS AND METHODS FOR ENHANCING DISCRIMINATORY RNA INTERFERENCE | UNIVERSITY OF MASSACHUSETTS (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-1789591-A2 | COMPOSITIONS, METHODS, AND KITS FOR IDENTIFYING AND QUANTITATING SMALL RNA MOLECULES | Applera Corporation (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1778864-A1 | CAPTURE PROBE DESIGN FOR EFFICIENT HYBRIDISATION | INFECTIO RECHERCHE Inc. (CA) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007041201-A2 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | APPLERA CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20060263771-A1 | Nucleoside or nucleotides having novel unnatural bases and utilization of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2006-11-23 | — | — | US | disclosed |
| US-20060234252-A1 | Methods and kits for methylation detection | APPLERA CORPORATION (US) | 2006-10-19 | — | — | US | disclosed |
| WO-2006076650-A2 | COMPOSITIONS, METHODS, AND KITS FOR SELECTIVE AMPLIFICATION OF NUCLEIC ACIDS | APPLERA CORPORATION (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1641942-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | Applera Corporation (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2006033928-A2 | COMPOSITIONS, METHODS, AND KITS FOR IDENTIFYING AND QUANTITATING SMALL RNA MOLECULES | APPLERA CORPORATION (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060057595-A1 | Compositions, methods, and kits for identifying and quantitating small RNA molecules | APPLERA CORPORATION (US) | 2006-03-16 | — | — | US | disclosed |
| WO-2006012727-A1 | CAPTURE PROBE DESIGN FOR EFFICIENT HYBRIDISATION | INFECTIO RECHERCHE INC. (CA) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006000085-A1 | HEPATITIS C INHIBITOR PEPTIDE ANALOGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | WO | disclosed |
| EP-1544294-A1 | NUCLEOSIDES OR NUCLEOTIDES HAVING NOVEL UNNATURAL BASES AND USE THEREOF | Riken (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | APPLIED BIOSYSTEMS, LLC | 2005-03-10 | — | — | US | disclosed |
| WO-2004111072-A2 | COMBINATORIAL NUCLEOBASE OLIGOMERS COMPRISING UNIVERSAL BASE ANALOGUES AND METHODS FOR MAKING AND USING SAME | APPLERA CORPORATION (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20040115665-A1 | Method for base sequencing and biologically active nucleic acids | RIKEN (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040077004-A1 | Use of nucleotide analogs in the analysis of oligonucleotide mixtures and highly multiplexed nucleic acid sequencing | TRUSTEES OF BOSTON UNIVERSITY, THE | 2004-04-22 | — | — | US | disclosed |
| US-6660229-B2 | Synthesizing extension products of the target nucleic acid in the presence of chain terminating nucleotides and mass-matched nucleotides; determining the mass of each extension product; and calculating a mass shift | THE TRUSTEES OF BOSTON UNIVERSITY | 2003-12-09 | — | — | US | disclosed |
| EP-1348035-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | Riken (JP) | 2003-10-01 | — | — | EP | disclosed |
| EP-1219607-A1 | INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044195-A2 | METHOD FOR BASE SEQUENCING AND BIOLOGICALLY ACTIVE NUCLEIC ACIDS | RIKEN (JP) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (26 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235339-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | CYP1A2 4325/4885TRPM4 3686/4885CYP2A6 4072/4885 |
| US-20200095591-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | CYP1A2 4325/4885TRPM4 3686/4885CYP2A6 4072/4885 |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | CYP1A2 3833/4885TRPM4 4680/4885CYP2A6 4077/4885 |
| US-10376533-B2 | Compositions and methods for treating viral infections | SLC10A1, HAVCR2, CYP3A43 | CYP1A2 183/4885TRPM4 3811/4885CYP2A6 160/4885 |
| US-20170029829-A1 | IMPORT OF UNNATURAL OR MODIFIED NUCLEOSIDE TRIPHOSPHATES INTO CELLS VIA NUCLEIC ACID TRIPHOSPHATE TRANSPORTERS | NUDT1, UPP1, UMPS | CYP1A2 4325/4885TRPM4 3686/4885CYP2A6 4072/4885 |
| US-20160038527-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP1A2 183/4885TRPM4 3811/4885CYP2A6 160/4885 |
| US-20110207690-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP1A2 183/4885TRPM4 3811/4885CYP2A6 160/4885 |
| US-20150374816-A1 | DESIGN OF SHORT OLIGONUCLEOTIDES AS VACCINE ADJUVANTS AND THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | CYP1A2 4414/4885TRPM4 1577/4885CYP2A6 3798/4885 |
| US-20080305966-A1 | Capture Probe Design for Efficient Hybridisation | DERA, DCLRE1B, DDX21 | CYP1A2 4453/4885TRPM4 4668/4885CYP2A6 2606/4885 |
| US-20070212704-A1 | COMPOSITIONS, METHODS, AND KITS FOR AMPLIFYING NUCLEIC ACIDS | RNGTT, POLRMT, RNASE1 | CYP1A2 2019/4885TRPM4 4746/4885CYP2A6 1373/4885 |
| US-20160016983-A1 | New Modified Nucleic Acid | RNGTT, RNASEH1, RNASE1 | CYP1A2 4596/4885TRPM4 3058/4885CYP2A6 2623/4885 |
| US-20180016243-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | CYP1A2 3498/4885TRPM4 4218/4885CYP2A6 3674/4885 |
| US-20230056324-A1 | METAL COMPLEXES | MCU, IMMT, SOD1 | CYP1A2 2830/4885TRPM4 393/4885CYP2A6 4118/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | CYP1A2 3498/4885TRPM4 4218/4885CYP2A6 3674/4885 |
| US-20050053979-A1 | Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same | DTYMK, UNG, TPR | CYP1A2 4876/4885TRPM4 1092/4885CYP2A6 4838/4885 |
| US-20130197066-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP1A2 183/4885TRPM4 3811/4885CYP2A6 160/4885 |
| US-20060057595-A1 | Compositions, methods, and kits for identifying and quantitating small RNA molecules | RNGTT, POLRMT, POLM | CYP1A2 4885/4885TRPM4 4682/4885CYP2A6 4523/4885 |
| US-10391166-B2 | Short oligonucleotides as vaccine adjuvants and therapeutic agents | TLR3, TLR5, TLR9 | CYP1A2 4568/4885TRPM4 1311/4885CYP2A6 4287/4885 |
| US-20120053226-A1 | DESIGN OF OLIGONUCLEOTIDE ANALOGS AS THERAPEUTIC AGENTS | TLR3, TLR5, TLR9 | CYP1A2 4663/4885TRPM4 600/4885CYP2A6 3293/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | CYP1A2 3498/4885TRPM4 4218/4885CYP2A6 3674/4885 |
| US-10513706-B2 | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters | NUDT1, UPP1, UMPS | CYP1A2 4325/4885TRPM4 3686/4885CYP2A6 4072/4885 |
| US-20250388955-A1 | METHYLATION DETECTION WITH A NON-NATURAL/UNNATURAL BASE | ALPG, MPG, OGG1 | CYP1A2 4550/4885TRPM4 4325/4885CYP2A6 3594/4885 |
| US-20100021914-A1 | OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY | RNASEH1, RNASE1, RNASEL | CYP1A2 4626/4885TRPM4 3600/4885CYP2A6 3821/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | CYP1A2 4001/4885TRPM4 4717/4885CYP2A6 4184/4885 |
| US-20170304344-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | SLC10A1, HAVCR2, CYP3A43 | CYP1A2 183/4885TRPM4 3811/4885CYP2A6 160/4885 |
| US-20260110026-A1 | METHODS FOR PROPAGATING AND MAPPING LOCATION OF NON-NATURAL BASES | UNG, DNMT1, TET1 | CYP1A2 2552/4885TRPM4 4598/4885CYP2A6 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.